NOV.DE Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk Loses Key Patent, Facing Ozempic and Wegovy Generics by 2031
The European Patent Office (EPO) revoked a key patent protecting Novo Nordisk’s blockbuster drugs Ozempic and Wegovy. The ruling could allow generic...
Novo Nordisk Licenses Oral Weight-Loss Pill in Deal Worth Up to $2.6B
Novo Nordisk has signed a licensing agreement with China’s Jiangsu Hengrui Pharmaceuticals for HRS-1596, an experimental once-weekly oral weight-loss pill. The...
Novo Nordisk Weighs NYSE Direct Listing, Citing Over 50% US Revenue
Novo Nordisk CEO Mike Doustdar told the Financial Times the company is open to a direct listing on the New York Stock Exchange. This potential move would...
Novo Nordisk pressured to diversify, citing risky reliance on Ozempic
Novo Nordisk shareholders are publicly urging the pharmaceutical giant to pursue acquisitions and new drug development. Investors aim to decrease the company's...
🔴 Novo Nordisk is trading 3.62% down today as investors focus on Capital Markets Day
Novo Nordisk is trading 3.62% down at €36.21 after closing at €37.57 on September 18, amid company-specific pressure as investors focus on its Capital Markets...
Novo Nordisk strikes $1.4B AI deal to turn injections into pills
Novo Nordisk partnered with Danish biotech Orbis Medicine to develop oral treatments for cardiometabolic diseases. The collaboration utilizes the AI-powered...
Novo Nordisk partners with Anthropic AI, previews new Wegovy pill data
Novo Nordisk has partnered with Anthropic to accelerate its drug discovery and development processes. The collaboration utilizes the Claude AI model to address...
Novo Nordisk rebrands to Novo, targeting the weight loss market
Novo Nordisk, the manufacturer of Ozempic and Wegovy, announced a rebrand to Novo on Monday. The company will maintain its legal name while adopting the...
Morgan Stanley Pulls the Plug on Novo Nordisk — But Can the GLP-1 Pioneer Reinvent Itself Before the Patent Clock Runs Out?
Shares of Novo Nordisk extended their slide on September 14, falling 3.5% to €36.89 and deepening a rout that has erased roughly 7.6% in just seven trading...
🔴 Novo Nordisk is trading 3.53% down today after Morgan Stanley downgrade over growth risks
Novo Nordisk is trading 3.53% down at €36.89 after Morgan Stanley downgraded the company from Equal-weight to Underweight on September 11, citing subdued...
Novo Nordisk Downgraded to Underweight, Morgan Stanley Cites Semaglutide Patent Cliff
Morgan Stanley downgraded Novo Nordisk from Equal-weight to Underweight on September 11, 2026. The bank maintained a price target of 250 Danish crowns. This...
🔴 Novo Nordisk is trading 3.2% down today despite China approving Wegovy for MASH
Novo Nordisk is trading at €37.02, down -3.20%, despite China approving Wegovy for MASH on September 10. - The approval expands Wegovy’s potential market, but...
Novo Nordisk wins China approval for Wegovy to treat liver disease
Novo Nordisk announced Thursday that China approved its weight-loss drug Wegovy for a new indication. The approval targets metabolic dysfunction-associated...
Novo Nordisk semaglutide reverses obesity in 40% of children, trial shows
Novo Nordisk reported positive topline results from its STEP Young Phase 3 trial. The study evaluated once-weekly semaglutide in children aged 6 to 12 living...
🔴 Novo Nordisk is trading 3.08% down today after Deutsche Bank downgrade to Sell
Novo Nordisk is trading 3.08% down now at €39.35 after Deutsche Bank downgraded the shares from Hold to Sell on August 27, 2026. - Analyst Emmanuel Papadakis...
🟢 Novo Nordisk is trading 3.31% up today after JPMorgan raised 2026 sales expectations
Novo Nordisk is trading at €41.35 (+3.31%) after JPMorgan raised its 2026 sales expectations and price target from DKK 250 to DKK 275. - JPMorgan cited...
Novo Nordisk Initiates New Late-Stage Study for Lower-Dose Oral Wegovy
Novo Nordisk has commenced a new late-stage study to evaluate the efficacy of smaller doses of its highly successful weight-loss drug, Wegovy. The trial, which...
Novo Nordisk dismisses Eli Lilly rivalry, comparing obesity drugs to sodas
Novo Nordisk executive Mike Doustdar stated the growing obesity market is not a zero-sum game against Eli Lilly. He believes investors underestimate the...
Novo Nordisk downgraded, citing Eli Lilly’s obesity market dominance
Berenberg downgraded Novo Nordisk A/S to hold from buy. The firm also trimmed its Copenhagen price target. Eli Lilly is increasing its dominance in oral and...
Novo Nordisk debuts Awiqli, first once-weekly basal insulin in the US
Novo Nordisk launched Awiqli® in the United States as the first once-weekly basal insulin for adults with type 2 diabetes. This treatment provides a convenient...